90
Participants
Start Date
March 7, 2023
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2029
Erdafitinib monotherapy
Patients will receive treatment with erdafitinib alone (cohort 1)
Cetrelimab and Erdafitinib combination
Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
RECRUITING
Ospedale Molinette, Turin
WITHDRAWN
A.O. Ordine Mauriziano, Ospedale Umberto I, Turi
RECRUITING
Complexo Hospitalario Universitario A Coruña, A Coruña
RECRUITING
IRCCS San Raffaele Hospital and Scientific Institute, Milan
RECRUITING
Hospital Universitario Lucus Augusti, Lugo
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
IUCT, Toulouse
RECRUITING
Fundación Instituto Valenciano De Oncología, Valencia
RECRUITING
CLCC Jean Perrin, Clermont-Ferrand
WITHDRAWN
CLCC Léon Bérard, Lyon
RECRUITING
Institut Mutualiste Montsouris, Paris
RECRUITING
Institut Gustave Roussy, Villejuif
RECRUITING
Hospital Clínic De Barcelona, Barcelona
RECRUITING
Hospital De Sabadell (Parc Taulí), Barcelona
RECRUITING
University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster
RECRUITING
The Royal Marsden NHS Foundation Trust, London
RECRUITING
Barts Health NHS Trust, London
RECRUITING
Charing Cross Hospital, London
RECRUITING
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
Janssen-Cilag Ltd.
INDUSTRY
Pivotal S.L.
INDUSTRY
Spanish Oncology Genito-Urinary Group
OTHER